Notably, the recent approval of a monoclonal antibody targeting IFNAR in SLE [19], together with the expanding deployment of JAK–STAT inhibitors that attenuate signaling downstream of IFN-I [20], marks a substantive advance toward precision medicine by enabling patient stratification and individualized therapeutic selection. Here, IFNAR1 is linked to systemic lupus erythematosus.